buvidal
camurus ab - buprenorphine - opioid-related disorders - other nervous system drugs - treatment of opioid dependence within a framework of medical, social and psychological treatment. treatment is intended for use in adults and adolescents aged 16 years or over.
buvidal solution for injection
camurus ab, sweden - buprenorphine - solution for injection - 24 mg
buvidal solution for injection
camurus ab, sweden - buprenorphine - solution for injection - 16 mg
buvidal solution for injection
camurus ab, sweden - buprenorphine - solution for injection - 8 mg
buvidal solution for injection
camurus ab, sweden - buprenorphine - solution for injection - 64 mg
buvidal solution for injection
camurus ab, sweden - buprenorphine - solution for injection - 32 mg
buvidal solution for injection
camurus ab, sweden - buprenorphine - solution for injection - 128 mg
buvidal solution for injection
camurus ab, sweden - buprenorphine - solution for injection - 96 mg
episil oral spray
camurus ab -
buvidal monthly buprenorphine 128 mg/0.36 ml modified release solution for injection
camurus pty ltd - buprenorphine, quantity: 128 mg - injection, solution - excipient ingredients: n-methyl-2-pyrrolidone; phosphatidyl choline; glyceryl dioleate; nitrogen - buvidal monthly is indicated for maintenance treatment of opioid dependence with prior stabilisation on buvidal weekly or sublingual buprenorphine or buprenorphine/naloxone within a framework of medical, social and psychological support.